TL;DR
Targeting oncogenic lncRNAs using ASO-based approaches represents a promising and rapidly evolving strategy in precision oncology and further optimization and well-structured clinical trials are required to facilitate the translation of these therapies into routine cancer treatment.
AI-generated by Semantic Scholar
